ImCare Biotech LLC
Immunotherapy platform for personalized cancer treatment using patient-derived immune cells
- Sector
- Medtech
- Headquarters
- Doylestown, PA
- Latest Form D
- $153K, Jul 2023
- Total capital
- $14.6M
- Federal grants
- $10.3M
- 9 awards · 2015–2025
- Rank in peer group#46 of 112
- Private capital raised
- $4.3M
- 5 Form D · last Jul 2023
- 39 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 9 pending · first 2024
- Rank in peer group#26 of 112
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · A novel multi-analyte algorithmic assay diagnostic for hepatocellular carcinoma (HCC).$365K
- Federal grantHealth and Human S · Phase II · A novel diagnostic Kit for Hepatocellular Carcinoma$1.3M
- Private capital raisedForm D · SEC · 5th filing$153K
- Federal grantHealth and Human S · Phase II · A novel diagnostic Kit for Hepatocellular Carcinoma$1.3M
- Private capital raisedForm D · SEC · 4th filing$368K
- Federal grantHealth and Human S · Phase II · A novel diagnostic Kit for Hepatocellular Carcinoma$4M
- Federal grantHealth and Human S · Phase II · A novel diagnostic Kit for Hepatocellular Carcinoma$1.4M
- Private capital raisedForm D · SEC · 3rd filing$1.3M
- Private capital raisedForm D · SEC · 2nd filing$1.8M
- Private capital raisedForm D · SEC · 1st filing$680K
Show 4 earlier federal awards
- Federal grantHealth and Human S · Phase II · A novel diagnostic biomarker for Hepatocellular Carcinoma(HCC)$1K
- Federal grantHealth and Human S · Phase II · A novel diagnostic biomarker for Hepatocellular Carcinoma(HCC)$655K
- Federal grantHealth and Human S · Phase II · A novel diagnostic biomarker for Hepatocellular Carcinoma(HCC)$657K
- Federal grantHealth and Human S · Phase II · A novel diagnostic biomarker for Hepatocellular Carcinoma(HCC)$633K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
59months
from ImCare Biotech LLC’s first federal award to its first private round.
- First federal award · Mar 2015
- Health and Human S · $633K
- First Form D · Mar 2020
- $680K · 1st Form D
- Awards before first raise
- 4 awards
An association in public records, not a cause or a prediction.
Standing among 112 peers
Line = medianMedtech · Instrument
- Federal grants#46 · top 41%
- Granted patents#26 · top 23%
- Linked publications#14 · top 13%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Xuanyong Yefei LuResearcherExecutive Officer, DirectorLinked by 2 patents · $9.9M in grants as PI
- Aaron Yefei LuExecutive Officer, DirectorNamed in SEC Form D filings
- Felix Y. LuExecutive Officer, DirectorNamed in SEC Form D filings
- Frank Y. FischerDirectorNamed in SEC Form D filings
- Lizhu Yefei TangDirectorNamed in SEC Form D filings
- Matthew Y. LeeDirectorNamed in SEC Form D filings
Show all 7 people
- Xuanyong Lu, PhDExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 11- PendingSerine Protease Inhibitor Kazal (spik) Compositions And MethodsUSPTOApplication 18953861
- GrantedAnti-serine Protease Inhibitor Kazal (spik) Antibodies, Immunoconjugates, And Methods Of UseUSPTOUS 12,377,162
- GrantedSerine Protease Inhibitor Kazal (spik) Compositions And MethodsUSPTOUS 12,180,301
Show all 11 patent records
- Serine Protease Inhibitor Kazal (spik) Compositions And MethodsNov 20, 2025 · Application 18953861Pending
- Anti-serine Protease Inhibitor Kazal (spik) Antibodies, Immunoconjugates, And Methods Of UseAug 5, 2025 · US 12,377,162Granted
- Serine Protease Inhibitor Kazal (spik) Compositions And MethodsDec 31, 2024 · US 12,180,301Granted
- Epitopes Of Anti-serine Protease Inhibitor Kazal (spik) AntibodiesFeb 8, 2024 · Application 17641780Pending
- Anti-serine Protease Inhibitor Kazal (spik) Antibodies, Immunoconjugates, And Methods Of UseApplication 62871565Pending
- Serine Protease Inhibitor Kazal (spik) Compositions And MethodsApplication PCTUS2019020999Pending
- Serine Protease Inhibitor Kazal (spik) Compositions And MethodsApplication 62639850Pending
- Serine Protease Inhibitor Kazal (spik) Compositions And MethodsApplication 62639345Pending
- Epitopes Of Anti-serine Protease Inhibitor Kazal (spik) AntibodiesApplication PCTUS2020046782Pending
- Anti-serine Protease Inhibitor Kazal (spik) Antibodies, Immunoconjugates, And Methods Of UseApplication PCTUS2020041228Pending
- Epitopes Of Anti-serine Protease Inhibitor Kazal (spik) AntibodiesApplication 62899024Pending
Recent research by its founders
- 3-D structure of Novel Liver Cancer Biomarker LC-SPIK and its Performance in Clinical Diagnosis of HCC20241 cites
- Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC)20241 cites
- EP05.01-016 Radiation Recall Pneumonitis (RRP) Induced by Immune Checkpoint Inhibitors (ICIs) after Thoracic Radiotherapy for Lung Cancer20220 cites
Related companies, and why
- NOVAFLUX, INC.Similar federal contract value in Medtech · null in contracts
- EXVADE BIOSCIENCE INCSimilar federal contract value in Medtech · null in contracts
- FILTRO MEDICAL INC.Similar federal contract value in Medtech · null in contracts
- Nortis, Inc.Similar federal contract value in Medtech · null in contracts
- JTAP TECHNOLOGIES, LLCSimilar federal contract value in Medtech · null in contracts
- Cordex Systems, IncSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .